Nivolumab

Nivolumab Reactions 1704, p281 - 2 Jun 2018 Pneumonitis: 3 case reports A study described three patients [ages and sexes not stated] who developed pneumonitis during treatment with nivolumab for non-small cell lung cancer. The patients started receiving nivolumab therapy at a dose of 3 mg/kg [route not stated] and developed moderate to severe grade pneumonitis [time to reactions onset not stated]. The first patient was treated with mycophenolate, prednisolone and methyprednisolone. The second patient received prednisolone and methylprednisolone, and the third patient received prednisolone only. Nivolumab was discontinued for the first two patients [outcomes not stated]. Author comment: "Immune-related adverse event such as pneumonitis can be a major concern in patients with lung cancer who may already have pre-morbid lung disease. This study describes the rates and effects of immune-related complications with nivolumab". Samaranayake C, et al. Pneumonitis and other immune related complications from nivolumab therapy in patient with non-small cell lung cancer: A descriptive study. Respirology 23 (Suppl. 1): 199 abstr. 175, Mar 2018. Available from: URL: http:// doi.org/10.1111/resp.13268 [abstract] - Australia 803323675 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Nivolumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/nivolumab-vJbOrv6iNo
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46924-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p281 - 2 Jun 2018 Pneumonitis: 3 case reports A study described three patients [ages and sexes not stated] who developed pneumonitis during treatment with nivolumab for non-small cell lung cancer. The patients started receiving nivolumab therapy at a dose of 3 mg/kg [route not stated] and developed moderate to severe grade pneumonitis [time to reactions onset not stated]. The first patient was treated with mycophenolate, prednisolone and methyprednisolone. The second patient received prednisolone and methylprednisolone, and the third patient received prednisolone only. Nivolumab was discontinued for the first two patients [outcomes not stated]. Author comment: "Immune-related adverse event such as pneumonitis can be a major concern in patients with lung cancer who may already have pre-morbid lung disease. This study describes the rates and effects of immune-related complications with nivolumab". Samaranayake C, et al. Pneumonitis and other immune related complications from nivolumab therapy in patient with non-small cell lung cancer: A descriptive study. Respirology 23 (Suppl. 1): 199 abstr. 175, Mar 2018. Available from: URL: http:// doi.org/10.1111/resp.13268 [abstract] - Australia 803323675 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off